Page last updated: 2024-11-06

azimexon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID47294
CHEMBL ID149579
SCHEMBL ID210599
MeSH IDM0067142

Synonyms (34)

Synonym
bm-12531
az, bm12.531
2-aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl]
1-[1-(2-cyanoaziridin-1-yl)-1-methyl-ethyl]aziridine-2-carboxamide
64118-86-1
azimexon
azimexon [inn]
azimexona [spanish]
2-(2-cyanaziridinyl-(1))-2-(2-carbamoylaziridinyl-(1))propane
einecs 264-679-7
azimexona [inn-spanish]
brn 0476876
1-((1-(2-cyano-1-aziridinyl)-1-methylethyl)-2-aziridinecarboxamide
1-(1-(2-cyano-1-aziridinyl)-1-methylethyl)-2-aziridinecarboxamide
bm 12531
2-aziridinecarboxamide, 1-(1-(2-cyano-1-aziridinyl)-1-methylethyl)-
azimexonum [inn-latin]
azimexone
azimexone [polish]
bm-12,531
bm12,531
CHEMBL149579
bm 12,531
1-[2-(2-cyanoaziridin-1-yl)propan-2-yl]aziridine-2-carboxamide
AKOS006271450
azimexonum
4nj842u6bz ,
azimexona
5-22-01-00009 (beilstein handbook reference)
unii-4nj842u6bz
SCHEMBL210599
1-(2-(2-cyanoaziridin-1-yl)propan-2-yl)aziridine-2-carboxamide
Q27260251
DTXSID60867055

Research Excerpts

Overview

Azimexon is an immunostimulant which shows therapeutic effects in tumor models and experimental infections in mice in vitro. It enhances T lymphocyte transformation in vitro and increases phagocytosis of latex particles by mouse peritoneal cells.

ExcerptReferenceRelevance
"Azimexon is an immunostimulant which shows therapeutic effects in tumor models and experimental infections in mice in vitro, enhances T lymphocyte transformation in vitro and increases phagocytosis of latex particles by mouse peritoneal cells."( Structural studies of immunomodulators. Part 2: Crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drug.
Srikrishnan, T, 1990
)
1.22

Pharmacokinetics

ExcerptReferenceRelevance
" administration could be best described by an open four-compartment-system yielding a terminal half-life of 74."( Pharmacokinetics of 14C-activity after the administration of 14C-azimexone in rats.
Abshagen, U; Haak, A; Hartung, K; Kaufmann, B; Koch, K; Wölfel, B, 1981
)
0.5

Dosage Studied

ExcerptRelevanceReference
" Seven of 11 anergic cancer patients have been immunorestored by a relatively low dosage of azimexon."( Immunorestoration of anergic cancer patients by azimexon.
Bonardelle, D; Goutner, A; Nasrat, F; Rameau, G, 1980
)
0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID121237Compound was tested for its ability to enhance nonspecific resistance to expt. fungal infection in mice immunosuppressed with cyclophosphamide and infected with candida albicans at 3x100 mg/kg/day; survival increase = 3/61998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.
AID121108Compound was tested for its ability to enhance nonspecific resistance to expt. fungal infection in mice immunosuppressed with cyclophosphamide and infected with candida albicans at 3x1 mg/kg/day; survival increase = 3/61998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.
AID121103Compound was tested for its ability to enhance nonspecific resistance to expt. fungal infection in mice immunosuppressed with cyclophosphamide and infected with candida albicans at 3x 0.1 mg/kg/day; survival increase = 3/61998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.
AID121233Compound was tested for its ability to enhance nonspecific resistance to expt. fungal infection in mice immunosuppressed with cyclophosphamide and infected with candida albicans at 3x10 mg/kg/day; survival increase = 3/61998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (93.18)18.7374
1990's3 (6.82)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.52%)5.53%
Reviews5 (10.87%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (82.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]